Atea Pharmaceuticals, Inc. (AVIR)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Atea Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Atea Pharmaceuticals, Inc. (AVIR) has returned 50.70% so far this year and 79.93% over the past 12 months.

Based on dividend-adjusted daily data since Oct 30, 2020, AVIR's average daily return is -0.02%, while the average monthly return is -0.27%.

Historically, 46% of months were positive and 54% were negative. The best month was Jan 2021 with a return of +74.7%, while the worst month was Oct 2021 at -66.8%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.

On a daily basis, AVIR closed higher 47% of trading days. The best single day was May 22, 2023 with a return of +36.8%, while the worst single day was Oct 19, 2021 at -66.0%.

Atea Pharmaceuticals, Inc. has an annualized alpha of -16.93%, beta of 0.96, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since November 02, 2020.

• This stock participated in 89.20% of S&P 500 Index downside but only -43.04% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

AVIR ranks 83 for risk / return — in the top 83% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Atea Pharmaceuticals, Inc. (AVIR) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Atea Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Atea Pharmaceuticals, Inc. was 97.12%, occurring on May 14, 2025. The portfolio has not yet recovered.

The current Atea Pharmaceuticals, Inc. drawdown is 93.92%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Atea Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Atea Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.